Publications 2024

Agost-Beltrán L, Zimmer C, Räder HJ, Kersten C, Schirmeister T, Rodríguez S, González FV (2024)
Rhodesain inhibitors on the edge of reversibility-irreversibility
Bioorg Chem, 153, 107830
DOI 10.1016/j.bioorg.2024.107830, PubMed 39306902

Elvebakken H, Venizelos A, Perren A, Couvelard A, Lothe IMB, Hjortland GO, Myklebust TÅ, Svensson J, Garresori H, Kersten C, Hofsli E, Detlefsen S, Vestermark LW, Knappskog S, Sorbye H (2024)
Treatment outcome according to genetic tumour alterations and clinical characteristics in digestive high-grade neuroendocrine neoplasms
Br J Cancer, 131 (4), 676-684
DOI 10.1038/s41416-024-02773-w, PubMed 38909137

Kallert E, Almena Rodriguez L, Husmann JÅ, Blatt K, Kersten C (2024)
Structure-based virtual screening of unbiased and RNA-focused libraries to identify new ligands for the HCV IRES model system
RSC Med Chem, 15 (5), 1527-1538
DOI 10.1039/d3md00696d, PubMed 38784459

Kaltbeitzel J, Kersten C, Wich PR (2024)
Amine-containing donepezil analogues as potent acetylcholinesterase inhibitors with increased polarity
RSC Med Chem, 15 (6), 2037-2044
DOI 10.1039/d3md00635b, PubMed 38911155

Kersten C, Archambault P, Köhler LP (2024)
Assessment of Nucleobase Protomeric and Tautomeric States in Nucleic Acid Structures for Interaction Analysis and Structure-Based Ligand Design
J Chem Inf Model, 64 (11), 4485-4499
DOI 10.1021/acs.jcim.4c00520, PubMed 38766733

Ree AH, Høye E, Esbensen Y, Beitnes AR, Negård A, Bernklev L, Tetlie LK, Fretland ÅA, Hamre HM, Kersten C, Hofsli E, Guren MG, Sorbye H, Nilsen HL, Flatmark K, Meltzer S (2024)
Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade
Oncoimmunology, 13 (1), 2372886
DOI 10.1080/2162402X.2024.2372886, PubMed 38952672

Ree AH, Šaltytė Benth J, Hamre HM, Kersten C, Hofsli E, Guren MG, Sorbye H, Johansen C, Negård A, Bjørnetrø T, Nilsen HL, Berg JP, Flatmark K, Meltzer S (2024)
First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer-the randomised METIMMOX trial
Br J Cancer, 130 (12), 1921-1928
DOI 10.1038/s41416-024-02696-6, PubMed 38664577

Publications 2023

Bjørnetrø T, Bousquet PA, Redalen KR, Trøseid AS, Lüders T, Stang E, Sanabria AM, Johansen C, Fuglestad AJ, Kersten C, Meltzer S, Ree AH (2023)
Next-generation sequencing reveals mitogenome diversity in plasma extracellular vesicles from colorectal cancer patients
BMC Cancer, 23 (1), 650
DOI 10.1186/s12885-023-11092-x, PubMed 37438741

Hammerschmidt SJ, Maus H, Weldert AC, Gütschow M, Kersten C (2023)
Improving binding entropy by higher ligand symmetry? - A case study with human matriptase
RSC Med Chem, 14 (5), 969-982
DOI 10.1039/d3md00125c, PubMed 37252099

Kallert E, Behrendt M, Frey A, Kersten C, Barthels F (2023)
Non-covalent dyes in microscale thermophoresis for studying RNA ligand interactions and modifications
Chem Sci, 14 (36), 9827-9837
DOI 10.1039/d3sc02993j, PubMed 37736627

Kersten C, Clower S, Barthels F (2023)
Hic Sunt Dracones: Molecular Docking in Uncharted Territories with Structures from AlphaFold2 and RoseTTAfold
J Chem Inf Model, 63 (7), 2218-2225
DOI 10.1021/acs.jcim.2c01400, PubMed 36884022

Knappskog S, Grob T, Venizelos A, Amstutz U, Hjortland GO, Lothe IM, Kersten C, Hofsli E, Sundlöv A, Elvebakken H, Garresori H, Couvelard A, Svensson J, Sorbye H, Perren A (2023)
Mutation Spectrum in Liquid Versus Solid Biopsies From Patients With Advanced Gastroenteropancreatic Neuroendocrine Carcinoma
JCO Precis Oncol, 7, e2200336
DOI 10.1200/PO.22.00336, PubMed 36753687

Køstner AH, Fuglestad AJ, Georgsen JB, Nielsen PS, Christensen KB, Zibrandtsen H, Parner ET, Rajab IM, Potempa LA, Steiniche T, Kersten C (2023)
Fueling the flames of colon cancer - does CRP play a direct pro-inflammatory role?
Front Immunol, 14, 1170443
DOI 10.3389/fimmu.2023.1170443, PubMed 37006231

Müller P, Meta M, Meidner JL, Schwickert M, Meyr J, Schwickert K, Kersten C, Zimmer C, Hammerschmidt SJ, Frey A, Lahu A, de la Hoz-Rodríguez S, Agost-Beltrán L, Rodríguez S, Diemer K, Neumann W, Gonzàlez FV, Engels B, Schirmeister T (2023)
Investigation of the Compatibility between Warheads and Peptidomimetic Sequences of Protease Inhibitors-A Comprehensive Reactivity and Selectivity Study
Int J Mol Sci, 24 (8)
DOI 10.3390/ijms24087226, PubMed 37108388

Rai P, Hoba SN, Buchmann C, Subirana-Slotos RJ, Kersten C, Schirmeister T, Endres K, Bufe B, Tarasov A (2023)
Protease detection in the biosensor era: A review
Biosens Bioelectron, 244, 115788
DOI 10.1016/j.bios.2023.115788, PubMed 37952320

Schwickert M, Zimmermann RA, Habeck T, Hoba SN, Nidoieva Z, Fischer TR, Stark MM, Kersten C, Lermyte F, Helm M, Schirmeister T (2023)
Covalent S-Adenosylhomocysteine-Based DNA Methyltransferase 2 Inhibitors with a New Type of Aryl Warhead
ACS Med Chem Lett, 14 (6), 777-787
DOI 10.1021/acsmedchemlett.3c00062, PubMed 37312859

Suzuki T, Kilbey A, Casa-Rodríguez N, Lawlor A, Georgakopoulou A, Hayman H, Yin Swe KL, Nordin A, Cantù C, Vantourout P, Ridgway RA, Byrne RM, Chen L, Verzi MP, Gay DM, Gil Vázquez E, Belnoue-Davis HL, Gilroy K, Køstner AH, Kersten C, Thuwajit C, Andersen DK, Wiesheu R, Jandke A, Blyth K et al. (2023)
β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Cancer Immunol Res, 11 (8), 1137-1155
DOI 10.1158/2326-6066.CIR-22-0644, PubMed 37309673

Venizelos A, Sorbye H, Elvebakken H, Perren A, Lothe IMB, Couvelard A, Hjortland GO, Sundlöv A, Svensson J, Garresori H, Kersten C, Hofsli E, Detlefsen S, Vestermark LW, Ladekarl M, Tabaksblat EM, Knappskog S (2023)
Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms
Endocr Relat Cancer, 30 (10)
DOI 10.1530/ERC-23-0057, PubMed 37410378

Zimmermann RA, Fischer TR, Schwickert M, Nidoieva Z, Schirmeister T, Kersten C (2023)
Chemical Space Virtual Screening against Hard-to-Drug RNA Methyltransferases DNMT2 and NSUN6
Int J Mol Sci, 24 (7)
DOI 10.3390/ijms24076109, PubMed 37047081

Publications 2022

Barthels F, Hammerschmidt SJ, Fischer TR, Zimmer C, Kallert E, Helm M, Kersten C, Schirmeister T (2022)
A low-cost 3D-printable differential scanning fluorometer for protein and RNA melting experiments
HardwareX, 11, e00256
DOI 10.1016/j.ohx.2022.e00256, PubMed 35509940

Brinkmann S, Semmler S, Kersten C, Patras MA, Kurz M, Fuchs N, Hammerschmidt SJ, Legac J, Hammann PE, Vilcinskas A, Rosenthal PJ, Schirmeister T, Bauer A, Schäberle TF (2022)
Identification, Characterization, and Synthesis of Natural Parasitic Cysteine Protease Inhibitors: Pentacitidins Are More Potent Falcitidin Analogues
ACS Chem Biol, 17 (3), 576-589
DOI 10.1021/acschembio.1c00861, PubMed 35262340

Cameron MG, Kersten C (2022)
Prospective case series of neuropathic cancer pain in patients treated with an EGFR-inhibitor
Palliat Med, 36 (7), 1154-1162
DOI 10.1177/02692163221102003, PubMed 35656645

Fischer TR, Meidner L, Schwickert M, Weber M, Zimmermann RA, Kersten C, Schirmeister T, Helm M (2022)
Chemical biology and medicinal chemistry of RNA methyltransferases
Nucleic Acids Res, 50 (8), 4216-4245
DOI 10.1093/nar/gkac224, PubMed 35412633

Fuglestad AJ, Meltzer S, Ree AH, McMillan DC, Park JH, Kersten C (2022)
The clinical value of C-reactive protein and its association with tumour location in patients undergoing curative surgery for colorectal cancer - a ScotScan collaborative study
Acta Oncol, 61 (10), 1248-1255
DOI 10.1080/0284186X.2022.2117572, PubMed 36068730

Hammerschmidt SJ, Huber S, Braun NJ, Lander M, Steinmetzer T, Kersten C (2022)
Thermodynamic characterization of a macrocyclic Zika virus NS2B/NS3 protease inhibitor and its acyclic analogs
Arch Pharm (Weinheim), 356 (4), e2200518
DOI 10.1002/ardp.202200518, PubMed 36480352

Kallert E, Fischer TR, Schneider S, Grimm M, Helm M, Kersten C (2022)
Protein-Based Virtual Screening Tools Applied for RNA-Ligand Docking Identify New Binders of the preQ₁-Riboswitch
J Chem Inf Model, 62 (17), 4134-4148
DOI 10.1021/acs.jcim.2c00751, PubMed 35994617

Knaff PM, Müller P, Kersten C, Wettstein L, Münch J, Landfester K, Mailänder V (2022)
Structure-Based Design of High-Affinity and Selective Peptidomimetic Hepsin Inhibitors
Biomacromolecules, 23 (6), 2236-2242
DOI 10.1021/acs.biomac.1c01011, PubMed 35593713

Meltzer S, Negård A, Bakke KM, Hamre HM, Kersten C, Hofsli E, Guren MG, Sorbye H, Flatmark K, Ree AH (2022)
Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer
Br J Cancer, 127 (12), 2227-2233
DOI 10.1038/s41416-022-02004-0, PubMed 36229579

Müller P, Maus H, Hammerschmidt SJ, Knaff PM, Mailänder V, Schirmeister T, Kersten C (2022)
Interfering with Host Proteases in SARS-CoV-2 Entry as a Promising Therapeutic Strategy
Curr Med Chem, 29 (4), 635-665
DOI 10.2174/0929867328666210526111318, PubMed 34042026

Schwickert M, Fischer TR, Zimmermann RA, Hoba SN, Meidner JL, Weber M, Weber M, Stark MM, Koch J, Jung N, Kersten C, Windbergs M, Lyko F, Helm M, Schirmeister T (2022)
Discovery of Inhibitors of DNA Methyltransferase 2, an Epitranscriptomic Modulator and Potential Target for Cancer Treatment
J Med Chem, 65 (14), 9750-9788
DOI 10.1021/acs.jmedchem.2c00388, PubMed 35849534

Wettstein L, Knaff PM, Kersten C, Müller P, Weil T, Conzelmann C, Müller JA, Brückner M, Hoffmann M, Pöhlmann S, Schirmeister T, Landfester K, Münch J, Mailänder V (2022)
Peptidomimetic inhibitors of TMPRSS2 block SARS-CoV-2 infection in cell culture
Commun Biol, 5 (1), 681
DOI 10.1038/s42003-022-03613-4, PubMed 35804152

Publications 2021

Cameron MG, Kersten C (2021)
Differential effects of epidermal growth factor receptor inhibitors in a single patient with neuropathic pain
BMJ Case Rep, 14 (3)
DOI 10.1136/bcr-2020-239385, PubMed 33771774

Cameron MG, Kersten C (2021)
WITHDRAWN: Neuropathic Cancer Pain in Patients Treated With an EGFR-Inhibitor
J Pain Symptom Manage (in press)
DOI 10.1016/j.jpainsymman.2021.06.018, PubMed 34161812

Johé P, Jaenicke E, Neuweiler H, Schirmeister T, Kersten C, Hellmich UA (2021)
Structure, interdomain dynamics, and pH-dependent autoactivation of pro-rhodesain, the main lysosomal cysteine protease from African trypanosomes
J Biol Chem, 296, 100565
DOI 10.1016/j.jbc.2021.100565, PubMed 33745969

Johe P, Jung S, Endres E, Kersten C, Zimmer C, Ye W, Sönnichsen C, Hellmich UA, Sotriffer C, Schirmeister T, Neuweiler H (2021)
Warhead Reactivity Limits the Speed of Inhibition of the Cysteine Protease Rhodesain
ACS Chem Biol, 16 (4), 661-670
DOI 10.1021/acschembio.0c00911, PubMed 33719398

Jung S, Fuchs N, Johe P, Wagner A, Diehl E, Yuliani T, Zimmer C, Barthels F, Zimmermann RA, Klein P, Waigel W, Meyr J, Opatz T, Tenzer S, Distler U, Räder HJ, Kersten C, Engels B, Hellmich UA, Klein J, Schirmeister T (2021)
Fluorovinylsulfones and -Sulfonates as Potent Covalent Reversible Inhibitors of the Trypanosomal Cysteine Protease Rhodesain: Structure-Activity Relationship, Inhibition Mechanism, Metabolism, and In Vivo Studies
J Med Chem, 64 (16), 12322-12358
DOI 10.1021/acs.jmedchem.1c01002, PubMed 34378914

Køstner AH, Nielsen PS, Georgsen JB, Parner ET, Nielsen MB, Kersten C, Steiniche T (2021)
Systemic Inflammation Associates With a Myeloid Inflamed Tumor Microenvironment in Primary Resected Colon Cancer-May Cold Tumors Simply Be Too Hot?
Front Immunol, 12, 716342
DOI 10.3389/fimmu.2021.716342, PubMed 34531864

Venizelos A, Elvebakken H, Perren A, Nikolaienko O, Deng W, Lothe IMB, Couvelard A, Hjortland GO, Sundlöv A, Svensson J, Garresori H, Kersten C, Hofsli E, Detlefsen S, Krogh M, Sorbye H, Knappskog S (2021)
The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms
Endocr Relat Cancer, 29 (1), 1-14
DOI 10.1530/ERC-21-0152, PubMed 34647903

Aamdal E, Jacobsen KD, Straume O, Kersten C, Herlofsen O, Karlsen J, Hussain I, Amundsen A, Dalhaug A, Nyakas M, Schuster C, Hagene KT, Holmsen K, Russnes HG, Skovlund E, Kaasa S, Aamdal S, Kyte JA, Guren TK (2021)
Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up
Int J Cancer, 150 (1), 100-111
DOI 10.1002/ijc.33768, PubMed 34449877

Publications 2020

Barthels F, Schirmeister T, Kersten C (2020)
BANΔIT: B'-Factor Analysis for Drug Design and Structural Biology
Mol Inform, 40 (1), e2000144
DOI 10.1002/minf.202000144, PubMed 32830452

Knaff PM, Kersten C, Willbold R, Champanhac C, Crespy D, Wittig R, Landfester K, Mailänder V (2020)
From In Silico to Experimental Validation: Tailoring Peptide Substrates for a Serine Protease
Biomacromolecules, 21 (4), 1636-1643
DOI 10.1021/acs.biomac.0c00240, PubMed 32191450

Mikkelsen HET, Vassbakk-Brovold K, Antonsen AJ, Berntsen S, Kersten C, Fegran L (2020)
Cancer Patients' Long-term Experiences of Participating in a Comprehensive Lifestyle Intervention Study While Receiving Chemotherapy
Cancer Nurs, 43 (1), 60-68
DOI 10.1097/NCC.0000000000000650, PubMed 30312192

Mitchell R, Mikolajczak M, Kersten C, Fleetwood-Walker S (2020)
ErbB1-dependent signalling and vesicular trafficking in primary afferent nociceptors associated with hypersensitivity in neuropathic pain
Neurobiol Dis, 142, 104961
DOI 10.1016/j.nbd.2020.104961, PubMed 32531343

Park JH, Fuglestad AJ, Køstner AH, Oliwa A, Graham J, Horgan PG, Roxburgh CSD, Kersten C, McMillan DC (2020)
Systemic Inflammation and Outcome in 2295 Patients with Stage I-III Colorectal Cancer from Scotland and Norway: First Results from the ScotScan Colorectal Cancer Group
Ann Surg Oncol, 27 (8), 2784-2794
DOI 10.1245/s10434-020-08268-1, PubMed 32248375

Welker A, Kersten C, Müller C, Madhugiri R, Zimmer C, Müller P, Zimmermann R, Hammerschmidt S, Maus H, Ziebuhr J, Sotriffer C, Schirmeister T (2020)
Structure-Activity Relationships of Benzamides and Isoindolines Designed as SARS-CoV Protease Inhibitors Effective against SARS-CoV-2
ChemMedChem, 16 (2), 340-354
DOI 10.1002/cmdc.202000548, PubMed 32930481

Publications 2019

Johannessen B, Syvertsen S, Kersten C, Berntsen S (2019)
Cancer-related fatigue: Patients' experiences of an intervention at a green care rehabilitation farm
Complement Ther Clin Pract, 37, 133-139
DOI 10.1016/j.ctcp.2019.101062, PubMed 31582199

Kersten C, Cameron MG (2019)
Oxaliplatin Plus Cetuximab: Are Uncertainties Unequivocally Settled?
J Clin Oncol, 37 (18), 1590-1591
DOI 10.1200/JCO.18.01759, PubMed 31046553

Kersten C, Cameron MG, Bailey AG, Fallon MT, Laird BJ, Paterson V, Mitchell R, Fleetwood-Walker SM, Daly F, Mjåland S (2019)
Relief of Neuropathic Pain Through Epidermal Growth Factor Receptor Inhibition: A Randomized Proof-of-Concept Trial
Pain Med, 20 (12), 2495-2505
DOI 10.1093/pm/pnz101, PubMed 31106835

Kersten C, Fleischer E, Kehrein J, Borek C, Jaenicke E, Sotriffer C, Brenk R (2019)
How To Design Selective Ligands for Highly Conserved Binding Sites: A Case Study Using N-Myristoyltransferases as a Model System
J Med Chem, 63 (5), 2095-2113
DOI 10.1021/acs.jmedchem.9b00586, PubMed 31423787

Meltzer S, Bakke KM, Rød KL, Negård A, Flatmark K, Solbakken AM, Kristensen AT, Fuglestad AJ, Kersten C, Dueland S, Seierstad T, Hole KH, Lyckander LG, Larsen FO, Schou JV, Patrick Brown D, Abrahamsson H, Redalen KR, Ree AH (2019)
Sex-related differences in primary metastatic site in rectal cancer; associated with hemodynamic factors?
Clin Transl Radiat Oncol, 21, 5-10
DOI 10.1016/j.ctro.2019.11.006, PubMed 31872084

Millies B, von Hammerstein F, Gellert A, Hammerschmidt S, Barthels F, Göppel U, Immerheiser M, Elgner F, Jung N, Basic M, Kersten C, Kiefer W, Bodem J, Hildt E, Windbergs M, Hellmich UA, Schirmeister T (2019)
Proline-Based Allosteric Inhibitors of Zika and Dengue Virus NS2B/NS3 Proteases
J Med Chem, 62 (24), 11359-11382
DOI 10.1021/acs.jmedchem.9b01697, PubMed 31769670

Publications 2018

Fey P, Chartomatsidou R, Kiefer W, Mottram JC, Kersten C, Schirmeister T (2018)
New aziridine-based inhibitors of cathepsin L-like cysteine proteases with selectivity for the Leishmania cysteine protease LmCPB2.8
Eur J Med Chem, 156, 587-597
DOI 10.1016/j.ejmech.2018.07.012, PubMed 30029081

Vassbakk-Brovold K, J Antonsen A, Berntsen S, Kersten C, Fegran L (2018)
Experiences of Patients With Breast Cancer of Participating in a Lifestyle Intervention Study While Receiving Adjuvant Chemotherapy
Cancer Nurs, 41 (3), 218-225
DOI 10.1097/NCC.0000000000000476, PubMed 28221215

Publications 2017

Rohde G, Kersten C, Vistad I, Mesel T (2017)
Spiritual Well-being in Patients With Metastatic Colorectal Cancer Receiving Noncurative Chemotherapy: A Qualitative Study
Cancer Nurs, 40 (3), 209-216
DOI 10.1097/NCC.0000000000000385, PubMed 27101099

Vassbakk-Brovold K, Berntsen S, Fegran L, Lian H, Mjåland O, Mjåland S, Nordin K, Seiler S, Kersten C (2017)
Lifestyle changes in cancer patients undergoing curative or palliative chemotherapy: is it feasible?
Acta Oncol, 57 (6), 831-838
DOI 10.1080/0284186X.2017.1413247, PubMed 29239243

Publications 2016

Cameron MG, Kersten C, Vistad I, van Helvoirt R, Weyde K, Undseth C, Mjaaland I, Skovlund E, Fosså SD, Guren MG (2016)
Palliative pelvic radiotherapy for symptomatic rectal cancer - a prospective multicenter study
Acta Oncol, 55 (12), 1400-1407
DOI 10.1080/0284186X.2016.1191666, PubMed 27332723

Køstner AH, Kersten C, Löwenmark T, Ydsten KA, Peltonen R, Isoniemi H, Haglund C, Gunnarsson U, Isaksson B (2016)
The prognostic role of systemic inflammation in patients undergoing resection of colorectal liver metastases: C-reactive protein (CRP) is a strong negative prognostic biomarker
J Surg Oncol, 114 (7), 895-899
DOI 10.1002/jso.24415, PubMed 27696432

Thomsen M, Kersten C, Sorbye H, Skovlund E, Glimelius B, Pfeiffer P, Johansen JS, Kure EH, Ikdahl T, Tveit KM, Christoffersen T, Guren TK (2016)
Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer
Oncotarget, 7 (46), 75013-75022
DOI 10.18632/oncotarget.12601, PubMed 27738330

Vassbakk-Brovold K, Kersten C, Fegran L, Mjåland O, Mjåland S, Seiler S, Berntsen S (2016)
Cancer patients participating in a lifestyle intervention during chemotherapy greatly over-report their physical activity level: a validation study
BMC Sports Sci Med Rehabil, 8, 10
DOI 10.1186/s13102-016-0035-z, PubMed 27099757

Publications 2015

Cameron MG, Kersten C, Vistad I, van Helvoirt R, Weyde K, Undseth C, Mjaaland I, Skovlund E, Fosså SD, Guren MG (2015)
Palliative pelvic radiotherapy for symptomatic incurable prostate cancer – A prospective multicenter study
Radiother Oncol, 115 (3), 314-20
DOI 10.1016/j.radonc.2015.05.021, PubMed 26091575

Mikkelsen HE, Brovold KV, Berntsen S, Kersten C, Fegran L (2015)
Palliative Cancer Patients' Experiences of Participating in a Lifestyle Intervention Study While Receiving Chemotherapy
Cancer Nurs, 38 (6), E52-8
DOI 10.1097/NCC.0000000000000235, PubMed 25730593

Pfeiffer P, Sorbye H, Qvortrup C, Karlberg M, Kersten C, Vistisen K, Lindh B, Bjerregaard JK, Glimelius B (2015)
Maintenance Therapy With Cetuximab Every Second Week in the First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation Group
Clin Colorectal Cancer, 14 (3), 170-6
DOI 10.1016/j.clcc.2015.03.002, PubMed 25956187

Vassbakk-Brovold K, Berntsen S, Fegran L, Lian H, Mjåland O, Mjåland S, Seiler S, Kersten C (2015)
Individualized Comprehensive Lifestyle Intervention in Patients Undergoing Chemotherapy with Curative or Palliative Intent: Who Participates?
PLoS One, 10 (7), e0131355
DOI 10.1371/journal.pone.0131355, PubMed 26176950

Publications 2014

Kjersem JB, Skovlund E, Ikdahl T, Guren T, Kersten C, Dalsgaard AM, Yilmaz MK, Fokstuen T, Tveit KM, Kure EH (2014)
FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab
BMC Cancer, 14, 340
DOI 10.1186/1471-2407-14-340, PubMed 24884501

Naume B, Synnestvedt M, Falk RS, Wiedswang G, Weyde K, Risberg T, Kersten C, Mjaaland I, Vindi L, Sommer HH, Sætersdal AB, Rypdal MC, Bendigtsen Schirmer C, Wist EA, Borgen E (2014)
Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer
J Clin Oncol, 32 (34), 3848-57
DOI 10.1200/JCO.2014.56.9327, PubMed 25366688

Publications 2013

Cameron MG, Kersten C, Guren MG, Fosså SD, Vistad I (2013)
Palliative pelvic radiotherapy of symptomatic incurable prostate cancer - a systematic review
Radiother Oncol, 110 (1), 55-60
DOI 10.1016/j.radonc.2013.08.008, PubMed 24044801

Cameron MG, Kersten C, Vistad I, Fosså S, Guren MG (2013)
Palliative pelvic radiotherapy of symptomatic incurable rectal cancer - a systematic review
Acta Oncol, 53 (2), 164-73
DOI 10.3109/0284186X.2013.837582, PubMed 24195692

Kersten C, Cameron MG, Mjåland S (2013)
Epithelial growth factor receptor (EGFR)-inhibition for relief of neuropathic pain-A case series
Scand J Pain, 4 (1), 3-7
DOI 10.1016/j.sjpain.2012.11.011, PubMed 29913887

Kersten C, Cameron MG, Mjåland S (2013)
Erratum to "Epithelial growth factor receptor (EGFR)-inhibition for relief of neuropathic pain-A case series" [Scand. J. Pain 4 (2013) 3-7]
Scand J Pain, 4 (2), 125
DOI 10.1016/j.sjpain.2013.02.001, PubMed 29913890

Kersten C, Cvancarova M, Mjåland S, Mjåland O (2013)
Does in-house availability of multidisciplinary teams increase survival in upper gastrointestinal-cancer?
World J Gastrointest Oncol, 5 (3), 60-7
DOI 10.4251/wjgo.v5.i3.60, PubMed 23671732

Kersten C, Louhimo J, Ålgars A, Lahdesmaki A, Cvancerova M, Stenstedt K, Haglund C, Gunnarsson U (2013)
Increased C-reactive protein implies a poorer stage-specific prognosis in colon cancer
Acta Oncol, 52 (8), 1691-8
DOI 10.3109/0284186X.2013.835494, PubMed 24102179

Publications 2012

Kersten C, Cameron MG (2012)
Cetuximab alleviates neuropathic pain despite tumour progression
BMJ Case Rep, 2012
DOI 10.1136/bcr.12.2011.5374, PubMed 22707700

Kersten C, Cameron MG, Oldenburg J (2012)
Truth in hope and hope in truth
J Palliat Med, 15 (1), 128-9
DOI 10.1089/jpm.2011.0209, PubMed 22268412

Kjersem JB, Ikdahl T, Guren T, Skovlund E, Sorbye H, Hamfjord J, Pfeiffer P, Glimelius B, Kersten C, Solvang H, Tveit KM, Kure EH (2012)
Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab
BMC Cancer, 12, 534
DOI 10.1186/1471-2407-12-534, PubMed 23167843

Kleist B, Xu L, Kersten C, Seel V, Li G, Poetsch M (2012)
Single nucleotide polymorphisms of the adult intestinal stem cell marker Lgr5 in primary and metastatic colorectal cancer
Am J Transl Res, 4 (3), 279-90
PubMed 22937206

Synnestvedt M, Borgen E, Wist E, Wiedswang G, Weyde K, Risberg T, Kersten C, Mjaaland I, Vindi L, Schirmer C, Nesland JM, Naume B (2012)
Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study
BMC Cancer, 12, 616
DOI 10.1186/1471-2407-12-616, PubMed 23259667

Publications 2011

Brunsvig PF, Kyte JA, Kersten C, Sundstrøm S, Møller M, Nyakas M, Hansen GL, Gaudernack G, Aamdal S (2011)
Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial
Clin Cancer Res, 17 (21), 6847-57
DOI 10.1158/1078-0432.CCR-11-1385, PubMed 21918169

Cameron MG, Kersten C, van Helvoirt R, Rohde G, Fosså SD, Vistad I (2011)
Patient reported outcomes of symptoms and quality of life among cancer patients treated with palliative pelvic radiation: a pilot study
BMC Res Notes, 4, 252
DOI 10.1186/1756-0500-4-252, PubMed 21777440

Kleist B, Xu L, Li G, Kersten C (2011)
Expression of the adult intestinal stem cell marker Lgr5 in the metastatic cascade of colorectal cancer
Int J Clin Exp Pathol, 4 (4), 327-35
PubMed 21577318

Publications 2007

Kersten C (2007)
Studies of tumor associated antigens and BMP-6 signallingin normal and neoplastic B cells
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 463, 1 b. (flere pag.)
BIBSYS 07018982x, ISBN 82-8072-409-5

Sivertsen EA, Huse K, Hystad ME, Kersten C, Smeland EB, Myklebust JH (2007)
Inhibitory effects and target genes of bone morphogenetic protein 6 in Jurkat TAg cells
Eur J Immunol, 37 (10), 2937-48
DOI 10.1002/eji.200636759, PubMed 17899540

Publications 2006

Kersten C, Dosen G, Myklebust JH, Sivertsen EA, Hystad ME, Smeland EB, Rian E (2006)
BMP-6 inhibits human bone marrow B lymphopoiesis--upregulation of Id1 and Id3
Exp Hematol, 34 (1), 72-81
DOI 10.1016/j.exphem.2005.09.010, PubMed 16413393

Publications 2005

Kersten C, Sivertsen EA, Hystad ME, Forfang L, Smeland EB, Myklebust JH (2005)
BMP-6 inhibits growth of mature human B cells; induction of Smad phosphorylation and upregulation of Id1
BMC Immunol, 6, 9
DOI 10.1186/1471-2172-6-9, PubMed 15877825

Publications 2004

Kersten C, Delabie J, Gaudernack G, Smeland EB, Fosså A (2004)
Analysis of the autoantibody repertoire in Burkitt's lymphoma patients: frequent response against the transcription factor ATF-2
Cancer Immunol Immunother, 53 (12), 1119-26
DOI 10.1007/s00262-004-0558-0, PubMed 15185015